Breast cancer survivors
Her2+ breast cancer
Men with breast cancer
People with a genetic mutation linked to cancer risk
Triple negative breast cancer
Women under 45
Women over 45
Special populations: People with early-stage (I or II) invasive breast cancer
While clinical trials track treatment side effects, fewer studies look at the burden of side effects on women undergoing breast cancer treatment or compare the side effects of different treatments. This study looks at the severity of side effects experienced by women treated for early-stage breast cancer. (4/11/17)
|At a glance||In-depth|
|Clinical trials||Resources and references|
|Questions for your doctor|
Documenting the frequency, severity, and burden of side effects (including nausea/vomiting, diarrhea, constipation, pain, arm swelling, difficulty breathing, and breast skin irritation) that women experience after treatment for early-stage (I or II) invasive breast cancer.
Few studies have looked at the full spectrum of side effects that women experience after treatment for early-stage breast cancer. It is important that health care providers are aware of the side effects that breast cancer patients can experience after treatment so they can incorporate this information into their treatment and survivorship plans with patients and provide early intervention when necessary.
This study showed that a substantial number of women experience side effects after breast cancer treatment. More work needs to be done to better understand and characterize the side effects associated with treatment. In the meantime, patients who experience side effects or who are about to start treatment should discuss their symptoms and /or concerns with their health care providers.
Health care providers always take care to ensure that a treatment is greater than its potential risks, but treatment can be more difficult with drugs such as cancer treatments where the dose needed often causes side effects.
While information is available regarding treatment side effects from clinical trial studies and health care claims, few studies have thoroughly examined the side effects that breast cancer patients experience after treatment outside of those settings. Additionally, participants of these studies are typically patients with late-stage breast cancer. Christopher Friese and colleagues from the University of Michigan School of Nursing and other institutions published research in 2017 in the journal Cancer that studied the side effects of women who were treated for their early-stage breast cancer.
What are the side effects, severity of those side effects, and patient burden associated with treatment for early-stage (I or II) invasive breast cancer?
This study used data from 1,884 women, ages 20-79, with early-stage (I or II) invasive breast cancer of any type. Women who had stage III or IV cancer or tumors bigger than 5 cm were excluded. The data was taken from the Los Angeles County and Georgia Surveillance, Epidemiology, and End Results (SEER) programs. Among the participants, 1,057 women were white, 321 were black, 315 were Latina, 141 were Asian and 50 were of unknown race or ethnicity. The patients received primary breast surgery (lumpectomy, unilateral or bilateral mastectomy) and may or may not have had radiation, chemotherapy, or both radiation and chemotherapy.
The researchers mailed surveys about two months after each woman’s surgery, asking patients to rank the severity of their side effects, including nausea/vomiting, diarrhea, constipation, pain, arm swelling, difficulty breathing, and breast skin irritation. Patients were also asked to fill out a survey about their physical health (the PROMIS measure) and health care services they used because of side effects. This allowed the researchers to measure the patient burden of side effects after treatment.
This study was conducted through patient surveys; researchers did not have access to patients’ health records. Studies such as these that rely solely on patients’ memories can include errors due to patients’ recall (for example, not remembering a side effect experienced or remembering it as more or less severe than it would be classified by a health care provider). Additionally, while the researchers recruited a fairly diverse group of women, because the study was limited to two geographic regions (Los Angeles and Georgia), the study conclusions may not be applicable to other areas. Finally, this study only included women with early-stage breast cancer; most had ER+/HER2- tumors. Additional work is needed to examine the effect in more advanced breast cancers. The researchers’ analysis did not separate early-stage breast cancers into different subtypes—depending on a patient’s subtype, individuals may have received different treatments compared to other patients, so the results may not be widely applicable to all patients.
This study suggests that almost half of women with early-stage invasive breast cancer experience at least one severe or very severe side effect after treatment. The study authors identified many clinical implications from this study, writing: “The toxicity burden faced by patients may be greater than acknowledged by clinicians, and warrants routine assessment during and between clinical visits. Differential toxicity patterns identified in this diverse, population-based sample of women may help clinicians when they review the risks and benefits of breast cancer treatment options.”
Share your thoughts on this review by taking our brief our brief survey